Infertility

 FRIDAY, NOVEMBER 11TH, 2016
HALL A
08:30-10:00 PCOS
Capsule PCOS: The most common endocrine disorder (5-10%) may be due to a combination of genetic and environmental factors that are possibly worsened by epigenetic factors, industrial endocrine disruptors or obesity exposures during the prenatal period
Chairpersons Zion Ben-Rafael, Israel
Jerome F. Strauss III, USA
08:30-09:00 Hormonal aspect of PCOS
Phillippe Bouchard, France
09:00-09:30 PCOS: Is there a preferred stimulation protocol for IVF?
Basil C. Tarlatzis, Greece
09:30-10:00 Genetics of PCOS
Jerome F. Strauss III, USA
Session Industry Session
12:00-13:40 OVARIAN STIMULATION
Capsule COH is a crucial step in ART. What is the place of AMH in the diagnosis and hCG in reaching optimal results?
Chairpersons Nick S. Macklon, UK
Fady I. Sharara, USA
12:10-12:40 Role of hCG in ovarian stimulation
Christophe Blockeel, Belgium
12:40-13:10 hCG versus LH
Manuela Simoni, Italy
13:10-13:40 Where AMH fits into controlled ovarian stimulation
Frank J.M. Broekmans, The Netherlands
14:30-16:00 ADENOMYOSIS
Capsule  For too long Adenomyosis was difficult to diagnose, classify, and treat. Did we overcome all these issues now?
Chairpersons Felice Petraglia, Italy
Victor Gomel, Canada
14:30-14:50 Are Adenomyosis and Endometriosis the same entity?
Stephan Gordts, Belgium
14:50-15:15 Classification of Adenomyosis
Gregoris Grimbizis, Greece
15:15-15:35 Management of Adenomyosis
Felice Petraglia, Italy
15:35-16:00 Different surgical options of Adenomyosis
Gregoris Grimbizis, Greece
16:30-18:00 MECHANICAL INFERTILITY
Capsule Mechanical factors that affect implantation are not common but lend themselves to treatment
Chairpersons Felice Petraglia, Italy
Stephan Gordts, Belgium
Mattheos Fraidakis, Greece
 16:30-16:50 Implications of Adenomyosis for fertility
Velja Mijatovic, The Netherlands
 16:50-17:35 Debate: Is Exploring the uterine cavity via ultrasound enough?
Yes: Andrea Tinelli, Italy
No: Mark Emanuel, The Netherlands
Discussion
 17:35-18:00 Caution: Endometrioma surgery can be very deleterious for the ovarian reserve
Jacques Donnez, Belgium
SATURDAY, NOVEMBER 12TH, 2016
HALL A
08:30-10:00 THE ENDOMETRIUM: WHAT IS NEW?
Capsule More forms of infertility will be subjected to treatment as the endometrium, the most neglected organ in reproduction, is revealing its secrets
Chairpersons Frank Broekmans, The Netherlands
Jacques Donnez,
Belgium
08:30-08:50 Embryo-Endometrium dialogue
Nick S. Macklon, UK
08:50-09:15 The emerging role of junctional zone in endometrium formation and implantation potential
Stephan Gordts, Belgium
09:15-09:35 Biomarkers or genetic tests for endometrial receptivity
Jose Horcajadas,
Spain
09:35-10:00 Endometrial regeneration: Stem cell therapy in Asherman Syndrome and Atrophic Endometrium
Antonio Pellicer, Spain
10:20-11:50 FERTILITY PRESERVATION FOR CANCER PATIENTS
Capsule Cancer patients should be informed of options for fertility preservation and future reproduction prior to cancer treatment (ASRM). Reproduction in the context of cancer raises a number of clinical and ethical issues
Chairpersons Norbert Gleicher, USA
Attila Vereczkey, Hungary
10:20-10:40 New frontier in vitrification for human oocytes and embryos
Masashige Kuwayama, Japan
10:40-11:05 Fertility preservation in the female: What are the prerequisites for success?
Marie M. Dolmans, Belgium
11:05-11:25 Fertility preservation: What is the best – oocyte vitrification or tissue freezing?
Antonio Pellicer, Spain
11:25-11:50 Fertility preservation for cancer patients: Are we over-using the technique?
Kirsten L. Tryde Macklon, Denmark
12:10-13:40 FERTILITY PRESERVATION : WHERE SHOULD WE GO FROM HERE?
Capsule Fertility preservation is often possible in cancer patients. However, in order to close the large gap between the need and the actual usage it is pertinent to produce interdisciplinary guidelines that will call upon every oncologist to discuss the options with every patient of reproductive age
Chairpersons Marie M. Dolmans, Belgium
Kirsten L. Tryde Macklon, Denmark
Fertility preservation: Balancing risks versus benefits
Annelies Bos, The Netherlands
Is there an ideal guideline?
Willianne Nelen, The Netherlands
How to increase awareness among oncologists: A gynecologist point of view?
Marie M. Dolmans, Belgium
Physicians’ perspective on fertility preservation in patients with cancer: Results of a survey performed by IVF Worldwide
Zeev Shoham, Israel
14:30-16:00 OVARIAN AGING
Capsule Ovarian aging is the main reason for ART failures
Chairpersons Rene Frydman, France
Stephan Gordts, Belgium
Attila Vereczkey, Hungary
14:30-14:50 Assessment of ovarian aging
Frank J.M. Broekmans, The Netherlands
14:50-15:10 Treatment of poor responders
Zion Ben-Rafael, Israel
15:10-15:30 When to revert to egg donation
Pedro Barri, Spain
15:30-16:00 SPECIAL LECTURE: Update on uterine transplantation and pregnancy outcome
Mats Brännstrom, Sweden
16:30-18:00 RTD ON BURNING CLINICAL ISSUES IN INFERTILITY WITH PANELISTS AND AUDIENCE INTERACTION
Moderators Zion Ben-Rafael, Israel
Bart C.J.M. Fauser,
The Netherlands
Discussants Rene Frydman, France
Nick S. Macklon,
UK
Simon Fishel,
UK
Jacques Cohen,
USA
Manuela Simoni,
Italy    
Questions 1.    Does ovarian stimulation for IVF affect oocyte / embryo quality?
2.    Is freeze all embryos a realistic strategy for all IVF patients? Who is doing it?
3.    Does GnRH agonist trigger for final oocyte maturation improve IVF outcome
4.    Current status of androgen supplementation to FSH ovarian stimulation for IVF
5.    Current status of LH / hCG supplementation to FSH ovarian stimulation for IVF
6.    All ovulation induction in PCOS should be replaced by IVF (the only way to effec-tively reduce multiple pregnancies)
7.    AUGMENT by OvaScience – what’s the evidence? what do practitioners need to know about what is being injected?
8.    PGS- clinical evidence, risk of litigation
9.    Should mosaic embryos be transferred?
10.   What KPI’s (Key Performances Indicators) should be used in an IVF lab?
11.   In 2017, should virtually all women undergoing IVF have single embryo transfer? Who has achieved it?
SUNDAY, NOVEMBER 13TH, 2016
HALL A
08:30-10:00 PERSONALIZED MEDICINE IN ACTION
Chairpersons Dominique de Ziegler, France
Zion Ben-Rafael, Israel
08:30-09:00 Personalization of medicine: Is fertility a good example?
Bart C.J.M. Fauser, The Netherlands
09:00-09:30 When should IVM be used
Dominique de Ziegler, France
09:30-10:00 The role of Progesterone revisited: A personal perspective
Phillipe Bouchard, France
10:30-12:00 HIGHLY CITED DUTCH RESEARCH IN REPRODUCTIVE MEDICINE
Capsule Three university medical centers from The Netherlands belong to the most cited research centers in Clinical Reproduction. Young members from these units will present their own work and put this in the larger perspective of the overall focus of the team
Chairpersons Bart C.J.M. Fauser, The Netherlands
Zion Ben-Rafael, Israel
10:30-10:50 Multi-follicular ovaries, presence and growth in health and disease
Marieke Verhoeven, (on behalf of Professor Lambalk team), VU University Medical Center, Amsterdam, The Netherlands
10:50-11:15 “Genetics of PCOS”
Yvonne V. Louwers, (on behalf of Professor Laven team), Erasmus University Medical Center, Rotterdam, The Netherlands
11:15-11:35 Androgens and cardiovascular risk in women with reproductive dysfunction
Nadine Daan, (on behalf of Professor Fauser team) UMC Utrecht, The Netherlands
11:35-12:00 Endometrial implantation
Robert P. Berkhout, (on behalf of Professor Repping team) AMC Amsterdam, The Netherlands
FRIDAY, NOVEMBER 11TH, 2016
HALL B
08:30-10:00 LABORATORY WORK CONTRIBUTING TO SUCCESS (I)
Capsule Quality control and risk management are cornerstones in IVF success
Chairpersons Laura Rienzi, Italy
Jacques Cohen
, USA
08:30-08:50 TQM (Total quality management): Why it matters?
Edith Coonen, Netherlands
08:50-09:15 Quality control in ART
Rita Vassena, Spain
09:15-09:35 In-vitro follicular culture
Evelyn Telfer, UK
09:35-10:00 Relevance of embryo competence for successful IVF, and role of GCSF
Bart C.J.M. Fauser, The Netherlands
10:20-11:50 LABORATORY WORK CONTRIBUTING TO SUCCESS (II)
Capsule How laboratory work can better results?
Chairpersons Manuela Simoni, Italy
Rita Vassena, Spain
10:20-10:40 What key performance indicators (KPI’s) should be used in an IVF lab?
Simon Fishel, UK
10:40-11:05 How to improve embryo quality in the IVF lab
Laura Rienzi, Italy
11:05-11:25 What is risk and how do you assess it?
Edith Coonen, Netherlands
11:25-11:50 Selecting the right sperm for ICSI
Laura Rienzi, Italy
12:10-13:40 BREAKING NEWS – ON THE MEANING OF UNEUPLOIDY
Capsule Research and innovation is the only way forward
Chairpersons Simon Fishel, UK
Magdelena Zernicka-Goetz, UK
12:10-12:30 Building the embryo: Plasticity and fate
Magdelena Zernicka-Goetz, UK
12:30-12:55 Development of the human embryo beyond day 7 in a dish
Marta N. Shahbazi, UK
12:55-13:15 What can these studies teach us about PGS?
Norber Gleicher, USA
13:15-13:40 Precision medicine in assisted conception: A multi-center observational treatment cohort study of the annexin A5 M2 haplotype as a biomarker for antithrombotic treatment to improve pregnancy outcome
Simon Fishel, UK
14:30-16:00 GENE EDITING: FROM BENCH TO CLINIC AND BACK TO MORATORIUM?
Capsule “Genome engineering” refers to the process of targeted modification of the genome. Like a “search mode” Cas9 can guide to specific site of intricate genomes by string of short RNA. Gene Editing of human germline with CRISPR/Cas9 technology can eventually transform medicine, basic research and biotechnology. How does it work? Should it be banned from use on gametes?
Chairpersons Jacques Cohen, USA
Anthony C.F. Perry
, UK
14:30-15:00 Technical aspects of gene editing in gametes and embryos
Anthony C.F. Perry, UK
15:00-15:30 Possible applications of gene editing in gametes and embryos
Rita Vassena, Spain
15:30-16:00 Ethical aspects and moratorium on gene editing in embryos
Heidi Mertes, Belgium
16:30-18:00 OVARIAN STIMULATION III
Organized by The Turkish Society of Reproductive Medicine
Chairperson Gurkan Uncu, Turkey
16:30-16:50 Monitoring ART cycles: What is the additional value of endocrine testing?
Barış Ata, Turkey
16:50-17:15 Individualized ovarian stimulation for ART
Gurkan Bozdağ, Turkey
17:15-17:35 Adjuvants to ovarian stimulation for ART
Gurkan Uncu, Turkey
17:35-18:00 Monitoring the luteal phase and individualized luteal support: Fact or fiction?
Ahmet Zeki Isik, Turkey
SATURDAY, NOVEMBER 12TH, 2016
HALL B
08:30-10:00 ALTERNATIVE PERSPECTIVES ON INFERTILITY CARE
Capsule The increasing need for quality reproductive treatments dictates involvement of patient’s organizations, societies and states in the regulation of the services
Chairpersons Bart C.J.M. Fauser, The Netherlands
Kamal Ahuja, UK
08:30-08:50 What patient organizations can do for infertile couples?
Elin Einarsdottir, Iceland
08:50-09:15 Context based infertility care
Jan A.M. Kremer, The Netherlands
09:15-09:35 Infertility and its implications for couples and children
Lone Schmidt, Denmark
09:35-10:00 From cross-border reproductive care to treatment at home: a turning of the tide?
Zeynep Gurtin & Kamal Ahuja, UK
Session LABORATORY WORK CONTRIBUTING TO SUCCESS (III)
Capsule Several recent and futuristic technologies which are in the forefront of laboratory research, including Mitochondrial Replacement Therapy (MRT) to avoid diseases transmission (which was recently approved in the UK for clinical use), nuclear transplantation or spindle transfer, mitochondrial supplementation and germ cell lines promise that innovation will keep fueling our field
Chairpersons Simon Fishel, UK
Barbara Wirleitner, Austria
10:20-10:40 MRT (Mitochondrial Replacement Therapy) and PGD as a first line treatment for mitochondrial disorders
Jacques Cohen, USA
10:40-11:05 Potential of germ line stem cells
Evelyn Telfer, UK
11:05-11:30 Epigenetics in reproduction
Rebecca Painter, The Netherlands
11:30-11:50 Laboratory instrumentation, data handling and quality control
Jacques Cohen, USA
12:10-13:40 METHODS FOR EMBRYO SELECTION: TOWARDS SET FOR ALL
Capsule Better selection methods might affect the rate of adoption of SET for IVF treatment however current methods to assess the preimplantation embryos like morphology, time lapse, PGS or markers are alone far from perfection. Can a combination of methods secure a better selection and implantation rate?
Chairpersons Rene Frydman, France
Jean Michel Foidart, France
12:10-12:30 Time-Lapse: Improved culture or just an expensive toy?
Thomas Ebner, Austria
12:30-12:55 What to do with embryos with reversed cleavage?
Diana Stein, Israel
13:20-13:40 The pros and cons of embryo selection
Thorir Hardarson, Sweden  
14:30-16:00 PGS: A FRIEND OR A FOE OF THE PATIENTS?
Capsule The debate is more acute now: While the technique seems to be improving the question now is can universal PGS improve the results of ART or worsen them?
Chairpersons Luca Gianaroli, Italy
Norbert Gleicher, USA
14:30-14:55 Optimizing embryo biopsy techniques
Simon Fishel, UK
14:55-15:15 Blastocoel analysis for PGS and the potential clinical value of mitochondrial screening assays
Luca Gianaroli, Italy
15:15-16:00 Debate: Overcoming the technical gaps will lead to PGS to all embryos… It’s only a matter of time
Yes:  Jacques Cohen, USA
No: PGS causes more damage than benefit
Norbert Gleicher, USA
Discussion